---
title: "ATYR Pharma | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286561781.md"
datetime: "2026-05-15T12:04:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286561781.md)
  - [en](https://longbridge.com/en/news/286561781.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286561781.md)
---

# ATYR Pharma | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -0.11, beating the estimate of USD -0.1457.

#### Cash and Investment Position

Cash, cash equivalents, restricted cash, and available-for-sale investments were $68,318 thousand as of March 31, 2026, compared to $80,922 thousand as of December 31, 2025.

#### Operating Expenses

Research and development expenses were $7,317 thousand for the first quarter of 2026, a decrease from $11,814 thousand for the first quarter of 2025.General and administrative expenses were $4,119 thousand for the first quarter of 2026, an increase from $3,959 thousand for the first quarter of 2025.Total operating expenses were $11,436 thousand for the first quarter of 2026, down from $15,773 thousand for the first quarter of 2025.

#### Operational Metrics

Loss from operations was - $11,436 thousand for the first quarter of 2026, an improvement from - $15,773 thousand for the first quarter of 2025.Total other income (expense), net, was $644 thousand for the first quarter of 2026, compared to $892 thousand for the first quarter of 2025.Consolidated net loss was - $10,792 thousand for the first quarter of 2026, an improvement from - $14,881 thousand for the first quarter of 2025.Net loss attributable to aTyr Pharma, Inc. was - $10,791 thousand for the first quarter of 2026, an improvement from - $14,880 thousand for the first quarter of 2025.

#### Balance Sheet Highlights

Total assets were $79,654 thousand as of March 31, 2026, compared to $93,003 thousand as of December 31, 2025.Total stockholders’ equity was $57,741 thousand as of March 31, 2026, compared to $67,288 thousand as of December 31, 2025.

#### Outlook / Guidance

aTyr Pharma, Inc. plans to submit an Investigational New Drug (IND) application in June 2026 for a new Phase 3 study of efzofitimod for pulmonary sarcoidosis, using Forced Vital Capacity (FVC) as the primary endpoint and King’s Sarcoidosis Questionnaire (KSQ)-Lung score as a key secondary endpoint.The company is also on track to complete enrollment in the Phase 2 EFZO-CONNECT™ study of efzofitimod in SSc-ILD in the first half of 2026.

### Related Stocks

- [ATYR.US](https://longbridge.com/en/quote/ATYR.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [Bureau Veritas: All resolutions passed at May 19, 2026 Shareholders' Meeting.](https://longbridge.com/en/news/286946080.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [FRONTERA ANNOUNCES FIRST QUARTER 2026 RESULTS | FECCF Stock News](https://longbridge.com/en/news/286507909.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)